Dual pathway inhibitor therapy switched from dual antiplatelet therapy reduces risk of recurrent in-stent occlusion after endovascular therapy for femoropopliteal in-stent occlusion

Abstract

Abstract Background Femoropopliteal (FP) in-stent occlusion (ISO), which increases the risk of repetition of reintervention and worsens the limb prognosis, is substantially encountered in clinical setting.1,2 Although previous study demonstrated that dual pathway inhibitor therapy (DPIT) reduced major adverse cardiovascular and limb events, whether this would be effective as anti-thrombotic therapy after endovascular therapy (EVT) for FP-ISO.3 Purpose To investigate whether DPIT reduces a risk of recurrent ISO after EVT for FP-ISO. Methods We retrospectively studied 117 limbs (chronic limb-threatening ischemia: 52%, chronic total occlusion: 74%) in 110 symptomatic patients with lower extremity arterial disease (male: 55%, diabetes mellitus: 49%) due to FP-ISO between August 2012 and October 2021. We compared the clinical outcomes of patients who were switched from dual antiplatelet therapy (DAPT) to DPIT with those who continued DAPT (DPIT group: 25 limbs in 25 patients, DAPT group: 92 limbs in 85 patients) after FP-ISO revascularization. The outcome measures were recurrent ISO and bleeding complications defined as the bleeding academic research criteria (BARC) and the International Society on Thrombosis and Haemostasis (ISTH). Cox proportional hazards regression models were used to identify prognostic factor of recurrent ISO. Results The 1-year cumulative incidence of recurrent ISO was significantly lower in DPIT group. (24.0±9.4% vs. 54.1±5.8%, p=0.037, Figure 1). The 1-year cumulative incidence of bleeding complications were similar between two groups (BRAC 3 or 5 bleeding: 4.2% vs. 2.4%, p=0.63), ISTH major bleeding: 12.6% vs. 11.4%, p=0.86) (Figure 2). Multivariate analysis revealed that DPIT group (hazard ratio [HR]: 0.34, 95% confidential interval [CI] 0.13-0.86, P=0.004) significantly associated with a reduced risk of recurrent ISO, whereas higher age (HR: 1.05, 95%CI 1.01-1.09, P=0.006) and poor BTK run-off (HR: 4.77, 95%CI 1.76-12.91, P=0.002) were significantly associated with an increased risk. Conclusion Switching from DAPT to DPIT after EVT for FP-ISO reduced the risk of recurrent ISO without increasing the risk of bleeding, while higher age and poor BTK run-off increased the risk of recurrent ISO.Figure 1Figure 2